
Cytophage Technologies Ltd. — Investor Relations & Filings
Cytophage Technologies Ltd. is a pioneering biotechnology company focused on developing synthetic bacteriophage products to prevent and treat bacterial infections, aiming to reduce and ultimately replace the use of conventional antibiotics. The company utilizes molecular genetic techniques and proprietary synthetic biology technology to create tailor-made, highly effective phages that are harmless to humans and animals. Cytophage's solutions address three primary markets: Animal Health (e.g., livestock illness prevention and growth enhancement), Food Safety (preventing disease spread without antibiotics), and Human Health (treating bacterial illnesses and hospital decontamination). A key competitive advantage is the rapid production timeline for targeted phages, enabling quick response to bacterial threats. The company is also engaged in advanced research, including the development of genetically engineered phage-based vaccines.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| News release - English.pdf | 2026-05-23 | English | |
| News release - English.pdf | 2026-05-23 | English | |
| News release - English.pdf | 2026-05-23 | English | |
| News release - English.pdf | 2026-05-23 | English | |
| News release - English.pdf | 2026-05-23 | English | |
| News release - English.pdf | 2026-04-15 | English |
Browse filings by year
6 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
9 filings
| |||||
| 46867178 | News release - English.pdf | 2026-05-23 | English | ||
| 46867162 | News release - English.pdf | 2026-05-23 | English | ||
| 46867146 | News release - English.pdf | 2026-05-23 | English | ||
| 46867131 | News release - English.pdf | 2026-05-23 | English | ||
| 46867121 | News release - English.pdf | 2026-05-23 | English | ||
| 34546772 | News release - English.pdf | 2026-04-15 | English | ||
| 34543854 | News release - English.pdf | 2026-04-15 | English | ||
| 34538131 | News release - English.pdf | 2026-04-15 | English | ||
| 34534051 | News release - English.pdf | 2026-04-15 | English | ||
|
2025
6 filings
| |||||
| 32366236 | Report of exempt distribution (45-106F1).pdf | 2025-12-08 | English | ||
| 32363854 | News release - English.pdf | 2025-11-29 | English | ||
| 32352508 | News release - English.pdf | 2025-11-05 | English | ||
| 32344908 | News release - English.pdf | 2025-10-16 | English | ||
| 32315686 | Report of exempt distribution (45-106F1) (amended).pdf | 2025-09-15 | English | ||
| 32261461 | News release - English.pdf | 2025-07-28 | English | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Burning Rock Biotech Ltd
A global diagnostics company specializing in precision onco…
|
BNR | US | Professional, scientific and te… |
|
Cabaletta Bio, Inc.
Develops engineered T cell therapies for B cell-mediated au…
|
CABA | US | Professional, scientific and te… |
|
Caliway
Develops small-molecule therapeutics for medical aesthetics…
|
6919 | TW | Professional, scientific and te… |
|
CALIX LIMITED
Develops industrial carbon capture and sustainable mineral …
|
CXL | AU | Professional, scientific and te… |
|
CAMBIUM BIO LIMITED
Clinical-stage developer of cellular therapies for ophthalm…
|
CMB | AU | Professional, scientific and te… |
|
CAMBRIDGE COGNITION HOLDINGS PLC
Develops digital solutions and a platform for CNS clinical …
|
COG | GB | Professional, scientific and te… |
|
CanBas Co.,Ltd.
A clinical-stage biopharmaceutical company developing novel…
|
4575 | JP | Professional, scientific and te… |
|
Captor Therapeutics S.A.
Develops Targeted Protein Degradation therapies for cancer …
|
CTX | PL | Professional, scientific and te… |
|
Cardiff Oncology, Inc.
A clinical-stage biotech developing cancer therapies that i…
|
CRDF | US | Professional, scientific and te… |
|
Cardio Diagnostics Holdings, Inc.
Develops AI-powered epigenetic and genetic tests for early …
|
CDIO | US | Professional, scientific and te… |
Cytophage Technologies Ltd. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/48283/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=48283 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=48283 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=48283 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 48283}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Cytophage Technologies Ltd. (id: 48283)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.